Bradykinin B2 Antagonist Matrix Tablets for Solubility and Extended Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing formulations for bradykinin B2 receptor antagonists with poor solubility face challenges in achieving reliable oral delivery, significant systemic exposure, and stable bioavailability, necessitating the development of extended-release formulations that are stable and manufacturable using established pharmaceutical technologies.
Innovation Solution
A pharmaceutical matrix tablet comprising a bradykinin B2 receptor antagonist with a chemical structure according to Formula (1) and at least one hydrophilic matrix-forming polymer, such as hydroxypropyl cellulose or hydroxypropyl methylcellulose, designed for extended release over 12 to 24 hours, incorporating the active ingredient in micronized or solubilized form and utilizing solid dispersions with carrier polymers like HPMCAS or copovidone to enhance solubility and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a bradykinin B2 receptor antagonist with poor aqueous solubility is formulated using conventional methods, then the formulation may be simple to manufacture, but the oral bioavailability and systemic exposure are insufficient
Solution Approach 1:
The patent employs solid dispersions combining the poorly soluble bradykinin B2 receptor antagonist with hydrophilic carriers (hydroxypropyl cellulose, hydroxypropyl methylcellulose, or their acetate succinate derivatives). This composite material system improves aqueous solubility and oral bioavailability while maintaining manufacturability through conventional tablet compression techniques. The hydrophilic carrier matrix facilitates drug dissolution and absorption without requiring complex formulation processes.
2Duration of action of moving object
If an extended-release formulation is designed for poor solubility compounds, then the duration of action is improved, but the reliability of drug release and bioavailability becomes uncertain
Solution Approach 1:
The patent utilizes the pH-dependent solubility characteristics of hydroxypropyl methylcellulose acetate succinate (HPMCAS) to achieve extended-release. The polymer remains insoluble in acidic gastric environment, preventing premature drug release, but dissolves in the higher pH of intestinal environment, enabling controlled drug release over 12-24 hours. This parameter-based approach ensures reliable and complete drug release while maintaining bioavailability stability.
Solution Approach 2:
The hydrophilic matrix-forming polymer acts as an intermediary between the poorly soluble drug and the aqueous environment. It forms a solubilizing matrix that gradually releases the drug, ensuring both extended duration of action and reliable bioavailability. The polymer mediates the drug's interaction with gastrointestinal fluids, protecting against pH and gastric motility variations.
3Quantity of substance
If the active ingredient is incorporated in micronized or solubilized form, then the solubility and dissolution rate are improved, but the manufacturing precision and stability may be compromised
Solution Approach 1:
The patent incorporates the active ingredient in micronized form (particle size 1-10 μm) locally within the hydrophilic matrix, creating regions of enhanced solubility and dissolution rate. The micronized drug particles are uniformly distributed throughout the hydroxypropyl cellulose or HPMCAS matrix, ensuring both improved solubility and formulation stability. This localized quality enhancement does not compromise manufacturing precision as the micronized powder can be handled using conventional mixing and compression techniques.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The matrix tablet provides reliable and complete drug release, overcoming solubility issues, ensuring stable bioavailability and manufacturability, with minimal impact from pH and gastric motility, suitable for chronic treatments like hereditary angioedema.
Implementation Method 1
the matrix-forming polymer, when compressed into a tablet and upon contact with water or aqueous media, may be capable of swelling or gelling
Implementation Method 2
the matrix-forming polymer, when compressed into a tablet and upon contact with water or aqueous media, may be capable of swelling or gelling
Implementation Method 3
The matrix tablet may comprise a solid dispersion of the bradykinin B2 receptor antagonist in amorphous form in a carrier
Data Source
AI summary
The invention relates to pharmaceutical matrix tablets for oral administration comprising a bradykinin B2 receptor antagonist having a chemical structure according to Formula (1), or a salt or solvate thereof, wherein R is deuterium or hydrogen: Formula (1) such as (S)-1V-(1-deutero-1-(3-chloro-5-fluoro-2-((2-methyl-4-(1-methyl-1//-1,2,4-triazol-5-yl)quinolin-8-yloxy)methyl)phenyl)ethyl)-2-(difluoromethoxy)acetamide. The matrix tablets reliably provide extended release of the bradykinin B2 receptor antagonist which makes them particularly suitable for prophylactic and/or chronic therapies. Therapeutic uses of the matrix tablets are provided.